ClinicalTrials.gg
CompletedNCT03006276Updated Jan 10, 2023Results posted

Efficacy, Tolerability, and Safety Study of DFN-15

A Phase 3 interventional study of DFN-15 Active and DFN-15 Placebo in Migraine Headache, sponsored by BioDelivery Sciences International. Completed at 45 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
622
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
85th of 609
622 · median 78
Started
2016
with 42 others
Phase 3
136 of 696
20 open now
Registered
329th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 85th largest by enrollment of the 609 interventional ones that give a count, is one of 43 that started in 2016, is one of 136 in phase 3, and was the 329th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.

03

Conditions studied

  • Migraine Headache

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for at least the past 12 months, with no more than 14 headache days per month, and with 48 hours of headache-free time between migraine attacks.
  2. Patients who have migraine with or without aura with onset before age 50 years
  3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale without treatment.
  4. Subjects who are willing and able to:

    1. Evaluate and record pain, migraine symptoms, and study drug effectiveness information in real-time using a subject eDiary for the duration of the study;
    2. Record each instance of the use of study drug and rescue medication in real-time using a subject eDiary for the duration of the study;
    3. Comply with all other study procedures and scheduling requirements.

Exclusion criteria

Exclusion Criteria:

  1. Minors, even if they are in the specified study age range
  2. Medication overuse:

    1. Opioids greater than or equal to 10 days during the 90 days prior to screening
    2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during the 90 days prior to screening (applies only if includes opioid and/or barbiturate)
    3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14 days a month during the 90 days prior to screening
    4. Triptans or ergots greater than or equal to 10 days a month during the 90 days prior to screening
  3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to screening. (If treated for cosmetic reasons, subjects may be included).
  4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to randomization.
  5. Patients who have received treatment with an drug or device within 30 days of randomization, or participated in a central nervous system clinical trial within 2 months prior to randomization
  6. Patients with positive screening test for [HIV], positive surface antigen (HBsAg), or positive virus [HCV] antibody
  7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the clinical research study site.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
622 participants (actual)

Study arms

  • Experimental
    DFN-15 Active

    DFN-15 Active

    Drug: DFN-15 Active

  • Placebo comparator
    DFN-15 Placebo

    DFN-15 Placebo

    Other: DFN-15 Placebo

Interventions

  • DrugDFN-15 Active

    Also known as: Celecoxib Oral Solution

  • OtherDFN-15 Placebo
06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1)

    Percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo in the DB1 period (defined as a reduction from predose moderate \[Grade 2\] or severe \[Grade 3\] pain to none \[Grade 0\]) during DB1.

    Time frame: 2 hours post dose

  2. Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose (DB1)

    Percentage of subjects who are free from their most bothersome symptom (MBS) among nausea, photophobia, and phonophobia at 2 hours postdose during DB1.

    Time frame: 2 hours post dose

Secondary outcomes

  1. Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)

    The percentage of subjects who were free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose during each DB treatment period were summarized by symptom, treatment group, and time point.

    Time frame: 15 minutes through 24 hours

  2. Time to Headache Pain Relief Postdose (DB1 and DB2)

    Time frame: 2 hours postdose

  3. Time to Headache Pain Freedom Postdose (DB1 and DB2)

    Time frame: 2 hours postdose

  4. Headache Pain Relief Postdose (DB1 and DB2)

    Headache pain relief during postdose in DB1 was defined as a reduction from moderate or severe pain at predose reduced to mild or none postdose, and for DB2 as moderate or severe pain at predose reduced to mild or none postdose, or mild pain at predose reduced to none postdose. Outcome measure shows percentage of subjects experiencing headache pain relief by time point.

    Time frame: 15 minutes to 24 hours postdose

  5. Headache Pain Freedom Postdose (DB1 and DB2)

    The percentage of subjects who were pain-free at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2), and 4, and 24 hours postdose during each DB treatment period were summarized by treatment group.

    Time frame: 15 minutes to 24 hours postdose

  6. Absence of Screening MBS at Time Points Postdose (DB1 and DB2)

    The percentage of subjects with their Screening MBS (most bothersome symptoms) among nausea, photophobia, and phonophobia (from eDiary data collection) absent at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose during each DB treatment period were summarized by treatment group and time point.

    Time frame: 15 minutes to 24 hours postdose

  7. Change in Functional Disability Score Postdose (DB1 and DB2)

    The values of the functional disability scale were: 0=no disability, able to function normally; 1=performance of daily activities mildly impaired, can still do everything but with difficulty; 2=performance of daily activities moderately impaired, unable to do some things; 3=performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary. A decrease in values indicates improvement from baseline.

    Time frame: 2 to 24 hours postdose

  8. Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)

    The percentage of subjects who were pain-free at 2 and 4 hours postdose during each DB treatment period among those subjects reporting cutaneous allodynia before dosing were summarized by treatment group and time point.

    Time frame: 2 to 4 hours postdose

  9. Headache Pain Freedom Among BMI Category (DB1 and DB2)

    The percentage of subjects who were pain-free at 2 and 4 hours postdose whose BMI was \<30 kg/m2 vs. subjects whose BMI was ≥30 kg/m2 during each DB treatment period were summarized by treatment group and time point.

    Time frame: 2 to 4 hours postdose

  10. Headache Pain Recurrence Postdose (DB1 and DB2)

    Headache pain recurrence was defined as pain-free at 2 hours postdose with pain reported as mild, moderate, or severe at 24 hours postdose. This outcome measure shows percentage of subjects who reported pain-free status and 2 hours postdose but subsequently reported recurrent pain at 24 hours postdose.

    Time frame: 2 to 24 hours postdose

  11. Sustained Headache Pain Relief Postdose (DB1 and DB2)

    Sustained headache pain relief was defined as pain relief at 2 hours postdose with no use of rescue medication and no worsening of headache pain within 2 to 24 hours postdose. This outcome measure shows the percentage of subjects who reported pain relief at 2 hours postdose with no use of rescue medication or worsening of headache pain through 24 hours postdose.

    Time frame: 2 to 24 hours postdose

  12. Sustained Headache Pain Freedom Postdose (DB1 and DB2)

    Sustained headache pain freedom was defined as pain-free at 2 hours postdose, with no use of rescue medication and no recurrence of headache pain within 2 to 24 hours postdose. This outcome measure shows percentage of subjects who were pain-free at 2 hours postdose without the use of rescue medication or recurrence of headache pain through 24 hours postdose.

    Time frame: 2 to 24 hours postdose

  13. Use of Rescue Medication Postdose (DB1 and DB2)

    The percentage of subjects who used rescue mediation after 2 hours (2 to 24 hours) postdose compared between DFN-15 and placebo in each DB period.

    Time frame: 2 to 24 hours postdose

  14. Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)

    Subject-rated treatment overall satisfaction was based on a 7-point scale at 2 and 4 hours postdose during each DB treatment period. The difference between the subject-rated study drug treatment satisfaction score at 2 and 4 hours postdose and the baseline PPMQ-R (Patient Perception of Migraine Questionnaire) response for the same question were summarized by treatment group (global satisfaction item at baseline asked about the subject's usual migraine treatment). The possible values of the subject treatment satisfaction scale were: 1=very satisfied, 2=satisfied, 3=somewhat satisfied, 4=neither satisfied nor dissatisfied, 5=somewhat dissatisfied, 6=dissatisfied, 7=very dissatisfied. A decrease in values indicates improvement from baseline.

    Time frame: 2 to 4 hours postdose

  15. Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)

    Patient Perception of Migraine Questionnaire-Revised had 30 questions assessing subject's satisfaction with migraine medication, including 3 global items \& 4 subscales (i.e., efficacy, function, ease of use, tolerability). A 5-point scale (1-Not At All to 5-Extremely) was used for tolerability subscale questions; a 7-point scale (1-Very Satisfied to 7-Very Dissatisfied) was used for all other subscales and global items. Total score was average of efficacy/function/ease of use subscale scores. Each subscale \& total scores were transformed to range from 0-100, with higher scores indicating better satisfaction or tolerability. Total raw score/global items were not transformed. The total raw score could range from 17 (min) to 119 (max), with lower scores indicating better satisfaction. Change from baseline scores at 24-hour-postdose for each subscale score, global item score, total score, \& total raw score were summarized by treatment group below.

    Time frame: 24 hours postdose

07

Results

Posted Jan 10, 2023

Participant flow

Double-blind Period 1 (DB1)
Participant flow — Double-blind Period 1 (DB1)
MilestonePlaceboDFN-15
Started311311
Not completed4342
Completed266265
Not completed4546
Double-blind Period 2 (DB2)
Participant flow — Double-blind Period 2 (DB2)
MilestonePlaceboDFN-15
Started278267
Not completed1620
Completed249242
Not completed2925

Outcome measures

PrimaryPercentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1)

Percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo in the DB1 period (defined as a reduction from predose moderate \[Grade 2\] or severe \[Grade 3\] pain to none \[Grade 0\]) during DB1.

Time frame:
2 hours post dose
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1)
percentage of subjectsPlacebo LOCFDFN-15 LOCFPlacebo OCDFN-15 OC
Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1)21.7 (16.8 to 27.1)35.6 (30.0 to 41.6)22.1 (17.2 to 27.7)35.8 (30.1 to 41.8)
Statistical analysis
  • Placebo LOCF vs DFN-15 LOCF · Fisher Exact · p = <0.001 · Odds ratio (or): 2.00 · 95% CI 1.36 to 2.94
  • Placebo OC vs DFN-15 OC · Fisher Exact · p = <0.001 · Odds ratio (or): 1.97 · 95% CI 1.34 to 2.89
PrimaryPercentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose (DB1)

Percentage of subjects who are free from their most bothersome symptom (MBS) among nausea, photophobia, and phonophobia at 2 hours postdose during DB1.

Time frame:
2 hours post dose
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose (DB1)
percentage of subjectsPlacebo LOCFDFN-15 LOCFPlacebo OCDFN-15 OC
Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose (DB1)44.8 (38.3 to 51.5)57.8 (51.1 to 64.2)45.4 (38.8 to 52.1)58.3 (51.6 to 64.8)
Statistical analysis
  • Placebo LOCF vs DFN-15 LOCF · Fisher Exact · p = 0.007 · Odds ratio (or): 1.68 · 95% CI 1.17 to 2.43
  • Placebo OC vs DFN-15 OC · Fisher Exact · p = 0.007 · Odds ratio (or): 1.69 · 95% CI 1.16 to 2.44
SecondaryFreedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)

The percentage of subjects who were free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose during each DB treatment period were summarized by symptom, treatment group, and time point.

Time frame:
15 minutes through 24 hours
Reported as:
Number · percentage of subjects
Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)
percentage of subjectsDB1 Placebo (Nausea)DB1 DFN-15 (Nausea)DB1 Placebo (Photophobia)DB1 DFN-15 (Photophobia)DB1 Placebo (Phonophobia)DB1 DFN-15 (Phonophobia)DB2 Placebo (Nausea)DB2 DFN-15 (Nausea)DB2 Placebo (Photophobia)DB2 DFN-15 (Photophobia)DB2 Placebo (Phonophobia)DB2 DFN-15 (Phonophobia)
15 minutes postdose16.8 (10.8 to 24.3)15.7 (10.0 to 23.0)8.8 (5.4 to 13.5)9.6 (5.9 to 14.4)15.7 (10.7 to 21.9)10.5 (6.4 to 16.1)14.5 (8.5 to 22.5)13.7 (7.7 to 22.0)7.5 (4.2 to 12.2)8.0 (4.6 to 12.9)8.5 (4.5 to 14.4)10.3 (6.0 to 16.1)
30 minutes postdose33.6 (25.9 to 41.9)32.9 (25.3 to 41.1)13.0 (9.0 to 18.1)20.1 (15.1 to 25.9)26.0 (20.0 to 32.9)24.6 (18.6 to 31.4)26.9 (19.2 to 35.8)31.4 (22.7 to 41.2)14.4 (9.8 to 20.0)21.9 (16.4 to 28.4)15.6 (10.2 to 22.3)27.4 (20.8 to 34.9)
45 minutes postdose43.8 (35.6 to 52.3)45.3 (37.1 to 53.7)20.2 (15.2 to 25.9)30.6 (24.7 to 37.0)26.7 (20.6 to 33.5)35.8 (29.0 to 43.0)41.8 (32.9 to 51.1)44.3 (34.7 to 54.3)22.1 (16.6 to 28.4)36.2 (29.5 to 43.3)25.8 (19.1 to 33.4)38.6 (31.1 to 46.4)
1 hour postdose49.3 (41.0 to 57.7)56.8 (48.4 to 64.9)26.5 (21.0 to 32.6)38.9 (32.6 to 45.5)38.3 (31.4 to 45.5)45.0 (37.8 to 52.4)52.5 (43.2 to 61.6)51.9 (42.0 to 61.7)27.9 (21.9 to 34.6)43.7 (36.7 to 50.9)34.2 (26.8 to 42.2)44.0 (36.3 to 51.9)
1.5 hours postdose58.5 (50.1 to 66.6)63.5 (55.2 to 71.3)36.0 (29.9 to 42.5)47.4 (40.9 to 54.0)47.2 (40.1 to 54.4)50.8 (43.5 to 58.1)60.2 (50.9 to 68.9)67.3 (57.5 to 76.0)35.4 (28.9 to 42.4)52.5 (45.3 to 59.6)43.2 (35.3 to 51.4)56.3 (48.4 to 63.9)
2 hours postdose62.2 (53.8 to 70.0)67.6 (59.4 to 75.0)44.4 (37.9 to 50.9)58.3 (51.7 to 64.7)54.5 (47.3 to 61.5)61.1 (53.9 to 68.1)66.9 (57.9 to 75.1)69.2 (59.5 to 77.7)45.9 (39.0 to 52.9)64.0 (56.9 to 70.6)48.7 (40.6 to 56.8)67.7 (60.0 to 74.7)
4 hours postdose75.5 (67.8 to 82.1)75.0 (67.2 to 81.7)61.2 (54.7 to 67.3)69.9 (63.6 to 75.7)72.9 (66.2 to 78.9)71.5 (64.6 to 77.8)74.2 (65.6 to 81.6)85.0 (76.9 to 91.2)62.8 (55.8 to 69.4)78.1 (71.7 to 83.6)59.0 (50.8 to 66.8)76.2 (69.0 to 82.4)
24 hours postdose91.4 (85.7 to 95.3)90.6 (84.7 to 94.8)85.2 (80.1 to 89.4)85.7 (80.6 to 89.9)89.7 (84.6 to 93.5)85.1 (79.3 to 89.8)87.1 (79.9 to 92.4)93.5 (87.1 to 97.4)84.6 (79.0 to 89.2)91.6 (86.9 to 95.0)81.5 (74.6 to 87.3)90.5 (85.1 to 94.5)
SecondaryTime to Headache Pain Relief Postdose (DB1 and DB2)
Time frame:
2 hours postdose
Reported as:
Mean · minutes
Time to Headache Pain Relief Postdose (DB1 and DB2)
minutesPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Time to Headache Pain Relief Postdose (DB1 and DB2)59.5 ± 29.8268.9 ± 43.6755.3 ± 29.2262.1 ± 29.58
SecondaryTime to Headache Pain Freedom Postdose (DB1 and DB2)
Time frame:
2 hours postdose
Reported as:
Mean · minutes
Time to Headache Pain Freedom Postdose (DB1 and DB2)
minutesPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Time to Headache Pain Freedom Postdose (DB1 and DB2)66.6 ± 32.3168.5 ± 31.0168.8 ± 25.0680.8 ± 25.80
SecondaryHeadache Pain Relief Postdose (DB1 and DB2)

Headache pain relief during postdose in DB1 was defined as a reduction from moderate or severe pain at predose reduced to mild or none postdose, and for DB2 as moderate or severe pain at predose reduced to mild or none postdose, or mild pain at predose reduced to none postdose. Outcome measure shows percentage of subjects experiencing headache pain relief by time point.

Time frame:
15 minutes to 24 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Relief Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
15 minutes postdose16.6 (12.1 to 22.0)13.4 (9.4 to 18.3)10.9 (7.1 to 15.8)11.7 (7.8 to 16.6)
30 minutes postdose28.9 (23.4 to 34.9)32.2 (26.6 to 38.2)27.5 (21.9 to 33.7)31.6 (25.7 to 38.0)
45 minutes postdose40.2 (34.2 to 46.5)46.5 (40.4 to 52.6)37.1 (31.0 to 43.5)47.7 (41.2 to 54.2)
1 hour postdose45.1 (38.9 to 51.4)56.8 (50.7 to 62.7)43.8 (37.4 to 50.3)56.1 (49.5 to 62.5)
1.5 hours postdose55.2 (48.9 to 61.4)70.0 (64.1 to 75.3)53.3 (46.8 to 59.7)66.4 (60.0 to 72.4)
2 hours postdose60.5 (54.3 to 66.4)74.5 (69.0 to 79.6)60.7 (54.2 to 66.8)74.4 (68.3 to 79.8)
4 hours postdose75.2 (69.5 to 80.3)79.6 (74.4 to 84.2)75.0 (69.1 to 80.3)82.2 (77.5 to 87.4)
24 hours postdose92.5 (88.7 to 95.4)92.4 (88.7 to 95.3)89.0 (84.4 to 92.6)93.8 (89.9 to 96.5)
SecondaryHeadache Pain Freedom Postdose (DB1 and DB2)

The percentage of subjects who were pain-free at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2), and 4, and 24 hours postdose during each DB treatment period were summarized by treatment group.

Time frame:
15 minutes to 24 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Freedom Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
15 minutes postdose1.3 (0.3 to 3.7)0.4 (0.0 to 2.2)1.4 (0.3 to 3.9)0.9 (0.1 to 3.2)
30 minutes postdose3.6 (1.6 to 6.6)3.0 (1.3 to 5.8)6.4 (3.6 to 10.3)6.8 (4.0 to 10.9)
45 minutes postdose8.6 (5.5 to 12.7)11.1 (7.6 to 15.4)11.7 (7.9 to 16.4)12.7 (8.7 to 17.6)
1 hour postdose12.8 (9.0 to 17.6)17.9 (13.6 to 23.0)15.8 (11.5 to 21.1)23.2 (18.0 to 29.1)
1.5 hours postdose17.4 (13.0 to 22.5)27.1 (21.9 to 32.8)25.2 (19.9 to 31.2)36.1 (30.0 to 42.6)
2 hours postdose——31.1 (25.4 to 37.4)46.2 (39.8 to 52.8)
4 hours postdose44.4 (38.3 to 50.6)56.4 (50.3 to 62.3)50.0 (43.6 to 56.4)61.9 (55.4 to 68.1)
24 hours postdose77.2 (71.7 to 82.1)77.3 (72.0 to 82.1)75.1 (69.2 to 80.4)82.9 (77.5 to 87.5)
SecondaryAbsence of Screening MBS at Time Points Postdose (DB1 and DB2)

The percentage of subjects with their Screening MBS (most bothersome symptoms) among nausea, photophobia, and phonophobia (from eDiary data collection) absent at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose during each DB treatment period were summarized by treatment group and time point.

Time frame:
15 minutes to 24 hours postdose
Reported as:
Number · percentage of subjects
Absence of Screening MBS at Time Points Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
15 minutes postdose10.6 (6.8 to 15.6)6.3 (3.4 to 10.5)8.0 (4.4 to 13.1)8.9 (5.2 to 14.1)
30 minutes postdose17.4 (12.7 to 23.0)17.3 (12.6 to 22.9)15.8 (10.9 to 21.8)22.9 (17.1 to 29.5)
45 minutes postdose22.5 (17.2 to 28.5)28.5 (22.7 to 34.8)27.5 (21.3 to 34.3)36.8 (30.0 to 44.1)
1 hour postdose25.0 (19.5 to 31.1)39.6 (33.2 to 46.2)35.8 (29.0 to 43.0)44.7 (37.5 to 52.1)
1.5 hours postdose38.7 (32.4 to 45.3)49.1 (42.5 to 55.8)42.6 (35.5 to 49.8)53.4 (46.1 to 60.6)
2 hours postdose44.8 (38.3 to 51.5)57.8 (51.1 to 64.2)50.0 (42.8 to 57.2)63.4 (56.1 to 70.2)
4 hours postdose61.3 (54.7 to 67.5)67.4 (61.0 to 73.4)60.7 (53.5 to 67.6)78.0 (71.5 to 83.7)
24 hours postdose86.0 (80.9 to 90.2)82.5 (77.0 to 87.1)83.7 (77.7 to 88.6)89.6 (84.4 to 93.5)
SecondaryChange in Functional Disability Score Postdose (DB1 and DB2)

The values of the functional disability scale were: 0=no disability, able to function normally; 1=performance of daily activities mildly impaired, can still do everything but with difficulty; 2=performance of daily activities moderately impaired, unable to do some things; 3=performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary. A decrease in values indicates improvement from baseline.

Time frame:
2 to 24 hours postdose
Reported as:
Mean · units on a scale
Change in Functional Disability Score Postdose (DB1 and DB2)
units on a scalePlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
2 hours postdose-0.7 ± 0.94-0.9 ± 1.00-0.6 ± 0.83-0.9 ± 0.87
4 hours postdose-1.1 ± 0.99-1.3 ± 1.01-1.0 ± 0.95-1.2 ± 0.94
24 hours postdose-1.8 ± 0.82-1.7 ± 0.84-1.5 ± 0.86-1.5 ± 0.88
SecondaryHeadache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)

The percentage of subjects who were pain-free at 2 and 4 hours postdose during each DB treatment period among those subjects reporting cutaneous allodynia before dosing were summarized by treatment group and time point.

Time frame:
2 to 4 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
2 hours postdose19.2 (9.6 to 32.5)38.0 (24.7 to 52.8)31.0 (17.6 to 47.1)54.3 (39.0 to 69.1)
4 hours postdose45.3 (31.6 to 59.6)56.0 (41.3 to 70.0)40.5 (25.6 to 56.7)56.5 (41.1 to 71.1)
SecondaryHeadache Pain Freedom Among BMI Category (DB1 and DB2)

The percentage of subjects who were pain-free at 2 and 4 hours postdose whose BMI was \<30 kg/m2 vs. subjects whose BMI was ≥30 kg/m2 during each DB treatment period were summarized by treatment group and time point.

Time frame:
2 to 4 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Freedom Among BMI Category (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
2 hours postdose (BMI<30)22.1 (15.8 to 29.7)31.5 (24.1 to 39.7)26.8 (19.7 to 34.8)41.9 (32.8 to 51.4)
4 hours postdose (BMI <30)41.7 (33.8 to 50.0)55.9 (47.4 to 64.1)50.0 (41.5 to 58.5)67.8 (58.6 to 76.1)
2 hours postdose (BMI>=30)21.1 (14.0 to 29.7)40.3 (31.8 to 49.3)37.3 (27.9 to 47.4)50.4 (41.2 to 59.6)
4 hours postdose (BMI>=30)47.8 (38.4 to 57.3)56.9 (48.0 to 65.6)50.0 (39.9 to 60.1)56.2 (46.9 to 65.2)
SecondaryHeadache Pain Recurrence Postdose (DB1 and DB2)

Headache pain recurrence was defined as pain-free at 2 hours postdose with pain reported as mild, moderate, or severe at 24 hours postdose. This outcome measure shows percentage of subjects who reported pain-free status and 2 hours postdose but subsequently reported recurrent pain at 24 hours postdose.

Time frame:
2 to 24 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Recurrence Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Headache Pain Recurrence Postdose (DB1 and DB2)14.0 (6.3 to 25.8)9.2 (4.3 to 16.7)6.6 (2.2 to 14.7)6.4 (2.6 to 12.7)
SecondarySustained Headache Pain Relief Postdose (DB1 and DB2)

Sustained headache pain relief was defined as pain relief at 2 hours postdose with no use of rescue medication and no worsening of headache pain within 2 to 24 hours postdose. This outcome measure shows the percentage of subjects who reported pain relief at 2 hours postdose with no use of rescue medication or worsening of headache pain through 24 hours postdose.

Time frame:
2 to 24 hours postdose
Reported as:
Number · percentage of subjects
Sustained Headache Pain Relief Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Sustained Headache Pain Relief Postdose (DB1 and DB2)43.4 (36.6 to 50.4)55.1 (48.0 to 62.1)49.7 (42.4 to 57.1)60.2 (52.8 to 67.3)
SecondarySustained Headache Pain Freedom Postdose (DB1 and DB2)

Sustained headache pain freedom was defined as pain-free at 2 hours postdose, with no use of rescue medication and no recurrence of headache pain within 2 to 24 hours postdose. This outcome measure shows percentage of subjects who were pain-free at 2 hours postdose without the use of rescue medication or recurrence of headache pain through 24 hours postdose.

Time frame:
2 to 24 hours postdose
Reported as:
Number · percentage of subjects
Sustained Headache Pain Freedom Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Sustained Headache Pain Freedom Postdose (DB1 and DB2)17.0 (12.2 to 22.7)26.8 (20.9 to 33.4)26.5 (20.3 to 33.3)39.8 (32.7 to 47.2)
SecondaryUse of Rescue Medication Postdose (DB1 and DB2)

The percentage of subjects who used rescue mediation after 2 hours (2 to 24 hours) postdose compared between DFN-15 and placebo in each DB period.

Time frame:
2 to 24 hours postdose
Reported as:
Number · percentage of subjects
Use of Rescue Medication Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Use of Rescue Medication Postdose (DB1 and DB2)30.1 (24.7 to 36.0)15.8 (11.7 to 20.7)18.4 (13.7 to 23.8)16.7 (12.2 to 22.0)
SecondarySubject-Rated Treatment Satisfaction Postdose (DB1 and DB2)

Subject-rated treatment overall satisfaction was based on a 7-point scale at 2 and 4 hours postdose during each DB treatment period. The difference between the subject-rated study drug treatment satisfaction score at 2 and 4 hours postdose and the baseline PPMQ-R (Patient Perception of Migraine Questionnaire) response for the same question were summarized by treatment group (global satisfaction item at baseline asked about the subject's usual migraine treatment). The possible values of the subject treatment satisfaction scale were: 1=very satisfied, 2=satisfied, 3=somewhat satisfied, 4=neither satisfied nor dissatisfied, 5=somewhat dissatisfied, 6=dissatisfied, 7=very dissatisfied. A decrease in values indicates improvement from baseline.

Time frame:
2 to 4 hours postdose
Reported as:
Mean · units on a scale
Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)
units on a scalePlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
2 hours postdose3.9 ± 1.903.3 ± 1.783.6 ± 1.973.1 ± 1.85
4 hours postdose3.7 ± 2.053.2 ± 1.903.5 ± 2.062.9 ± 1.80
SecondarySubject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)

Patient Perception of Migraine Questionnaire-Revised had 30 questions assessing subject's satisfaction with migraine medication, including 3 global items \& 4 subscales (i.e., efficacy, function, ease of use, tolerability). A 5-point scale (1-Not At All to 5-Extremely) was used for tolerability subscale questions; a 7-point scale (1-Very Satisfied to 7-Very Dissatisfied) was used for all other subscales and global items. Total score was average of efficacy/function/ease of use subscale scores. Each subscale \& total scores were transformed to range from 0-100, with higher scores indicating better satisfaction or tolerability. Total raw score/global items were not transformed. The total raw score could range from 17 (min) to 119 (max), with lower scores indicating better satisfaction. Change from baseline scores at 24-hour-postdose for each subscale score, global item score, total score, \& total raw score were summarized by treatment group below.

Time frame:
24 hours postdose
Reported as:
Mean · units on a scale
Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)
units on a scalePlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Total Score-0.657 ± 30.99294.367 ± 33.71463.544 ± 32.37913.940 ± 31.7753
Total Raw Score0.835 ± 12.0599-1.254 ± 12.9334-0.744 ± 12.3973-1.448 ± 12.3105
Efficacy-4.196 ± 39.00512.292 ± 40.89580.385 ± 39.72933.604 ± 39.9214
Function-0.020 ± 40.30937.931 ± 42.89136.239 ± 39.82138.169 ± 38.6639
Ease of Use2.247 ± 28.53482.876 ± 29.38164.009 ± 28.65880.047 ± 28.8880
Tolerability5.99 ± 16.5218.45 ± 15.9309.01 ± 15.3016.72 ± 15.565
Medication Effectiveness (Global Item)0.7 ± 2.590.2 ± 2.770.2 ± 2.640.2 ± 2.63
Side Effects (Global Item)-0.3 ± 2.052.6 ± 1.36-0.7 ± 1.88-0.3 ± 1.92
Overall Satisfaction (Global Item)0.5 ± 2.670.1 ± 2.750.1 ± 2.620.0 ± 2.48

Adverse events

Collected over Per protocol, the maximum dosing timeframe for DB2 was 10 weeks; therefore, the maximum AE collection window was 11 weeks total.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo DB10/282 (0%)2/282 (0.7%)9/282 (3.2%)
DFN-15 DB10/285 (0%)0/285 (0%)17/285 (6%)
Placebo DB20/249 (0%)0/249 (0%)5/249 (2%)
DFN-15 DB20/244 (0%)0/244 (0%)6/244 (2.5%)
Overall0/567 (0%)2/567 (0.4%)37/567 (6.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2Overall
Road traffic accidentInjury, poisoning and procedural complications1/2820/2850/2490/2441/567
Non-cardiac chest painNervous system disorders1/2820/2850/2490/2441/567
Most frequent other events
Most frequent other events
EventPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2Overall
DysgeusiaNervous system disorders4/28212/2852/2494/24422/567
NauseaGastrointestinal disorders5/2829/2853/2492/24419/567

Baseline characteristics

Baseline characteristics list the safety population (i.e., all subjects who were dosed during DB1). Note that there are 2 subjects in the placebo group and 2 subjects in the DFN-15 group, for whom no postdose efficacy data were collected. These individuals are, therefore, included in the baseline subject counts but are not included subsequent results reporting.

Age, Continuous
Age, Continuous(years)DB1 PlaceboDB1 DFN-15Total
Mean40.1 ± 12.5940.5 ± 11.6840.3 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)DB1 PlaceboDB1 DFN-15Total
Female242252494
Male403373
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB1 PlaceboDB1 DFN-15Total
Hispanic or Latino384078
Not Hispanic or Latino243242485
Unknown or Not Reported134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB1 PlaceboDB1 DFN-15Total
American Indian or Alaska Native011
Asian6511
Native Hawaiian or Other Pacific Islander022
Black or African American5075125
White219198417
More than one race000
Unknown or Not Reported7411
08

Study locations

45 sites
  • Site 744
    Birmingham, Alabama 35216, United States
  • Site 727
    Phoenix, Arizona 85018, United States
  • Site 723
    Little Rock, Arkansas 72211, United States
  • Site 718
    Rogers, Arkansas 72758, United States
  • Site 709
    Los Angeles, California 90017, United States
  • Site 708
    Orange, California 92868, United States
  • Site 729
    San Diego, California 92103, United States
  • Site 725
    Santa Monica, California 90404, United States
  • Site 738
    Simi Valley, California 93065, United States
  • Site 733
    Upland, California 91786, United States
  • Site 726
    Colorado Springs, Colorado 80907, United States
  • Site 735
    DeLand, Florida 32720, United States
  • Site 711
    Hialeah, Florida 33016, United States
  • Site 721
    Jacksonville, Florida 32256, United States
  • Site 740
    Blue Ridge, Georgia 30513, United States
  • Site 720
    Decatur, Georgia 30030, United States
  • Site 734
    West Des Moines, Iowa 50265, United States
  • Site 739
    Prairie Village, Kansas 66208, United States
  • Site 713
    Wichita, Kansas 67205, United States
  • Site 706
    Shreveport, Louisiana 71105, United States
  • Site 712
    Baltimore, Maryland 21236, United States
  • Site 703
    Boston, Massachusetts 02131, United States
  • Site 730
    New Bedford, Massachusetts 02740, United States
  • Site 704
    Minneapolis, Minnesota 55402, United States
  • Site 736
    Hazelwood, Missouri 63042, United States
  • Site 737
    Springfield, Missouri 65807, United States
  • Site 745
    Las Vegas, Nevada 89103, United States
  • Site 716
    Berlin, New Jersey 08009, United States
  • Site 746
    Amherst, New York 14226, United States
  • Site 705
    Manhattan, New York 10018, United States
  • Site 743
    Williamsville, New York 14221, United States
  • Site 715
    Raleigh, North Carolina 27612, United States
  • Site 728
    Cincinnati, Ohio 45255, United States
  • Site 707
    Dayton, Ohio 45424, United States
  • Site 701
    Oklahoma City, Oklahoma 73103, United States
  • Site 741
    Salem, Oregon 97301, United States
  • Site 717
    Media, Pennsylvania 19063, United States
  • Site 731
    Philadelphia, Pennsylvania 19107, United States
  • Site 742
    Lincoln, Rhode Island 02865, United States
  • Site 710
    Anderson, South Carolina 29621, United States
  • Site 724
    Chattanooga, Tennessee 37421, United States
  • Site 719
    Austin, Texas 78731, United States
  • Site 702
    Plano, Texas 75024, United States
  • Site 714
    Virginia Beach, Virginia 23454, United States
  • Site 722
    Bellevue, Washington 98007, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Nov 2017 and a completion of May 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2023, 5 years 2 months after primary completion. A results delay was requested in Dec 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2016
First posted
Dec 30, 2016
Start
Dec 2016
Primary completionActual
Nov 2017
CompletionActual
May 2019
Results delay requested
Dec 24, 2018
Results first posted
Jan 10, 2023
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03006276
Lead sponsor
BioDelivery Sciences International
Responsible party
Sponsor
First posted
Dec 30, 2016
Start date
Dec 2016
Primary completion
Nov 2017
Completion
May 2019
Results posted
Jan 10, 2023
Last update
Jan 10, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion